**Paper Title (16 Bold)**

Author (14)

*1Channabasweshwar Pharmacy College, Latur, Maharashtra, India.*

*M. Pharm, Ph.D.*

*Associate Professor and Head,*

*Department of Pharmaceutics, Channabasweshwar Pharmacy College, Kava Road, Latur-413512, Dist. Latur. (MS)*

*Corresponding Author: xxxx.(10)*

**ABSTRACT**: **(10 Bold)** Orally disintegrating tablets (ODTs) are a rapidly growing category of dosage form in the pharmaceutical industry which has received ever-increasing demand during the last decade. They especially find application in target category like geriatrics and pediatrics. There are three main manufacturing methods used for the production of ODTs, namely, freeze drying, molding and compression method. Also, different technologies are routinely used for the manufacturing of ODTs i.e, Orasolv®, Durasolv®, WOWTAB®, Flash tab®, Zydis®, Quicksolv® and Lyoc® etc. Some methods of manufacturing ODTs are complex, require multiple processes and don’t provide all ODTs ideal properties. For example, freeze drying and molding provide very light and porous products which disintegrate very rapidly, but they are expensive and produce fragile products. On the other hand, compression method is the easiest and cost effective method for the production of ODTs. Orally disintegrating tablets containing 20 mg of Furosemide were manufactured using direct compression method. Experiments were evaluated for effects of formulation parameters like type & concentration of diluents, concentration of disintegrating agent and their interactions on Furosemide ODTs properties, and Microcrystalline cellulose, Mannitol were used as diluents of different properties, in addition to croscarmellose sodium (CCS), crosspovidone and the fenugreek powder which was used as a natural superdisintegrant in combination with the synthetic. The obtained results revealed that disintegration time of the optimized ODTs formula (14 sec. to 30 sec). ODTs composed of crosspovidone in combination with natural superdisintegrants 5 % level was chosen as optimized formula, as it showed the lowest disintegration time with the highest drug release up to 97.73%. Furthermore, hardness of the manufactured tablets was not significantly affected by the use of crospovidone and CCS. Finally, it was concluded that Furosemide oral disintegrating tablets were developed using crosspovidone and Fenugreek powder. These tablets provided low disintegration time and high hardness that are acceptable for ODTs. Thus the present work explores a novel technique of formulating palatable ODTs which gave better balance between disintegration time and hardness of the tablet.

**KEYWORDS: (10 Bold)**  Orally disintegrating tablet, Superdisintegrants (synthetic, natural), Furosemide.

**--------------------------------------------------------------------------------------------------------------------------------------**

Date of Submission: xx-xx-xxxx Date of acceptance: xx-xx-xxxx

**--------------------------------------------------------------------------------------------------------------------------------------**

1. **INTRODUCTION (10 Bold)**

Recent developments in the technology have prompted scientists to develop orally disintegrating tablets with improved patient compliance and convenience. Orally disintegrating tablets are solid dosage forms that disintegrate rapidly when placed upon the tongue, usually within a matter of seconds. ODTs are intended to disperse, dissolve, or disintegrate quickly in the mouth cavity due to saliva, which results in release of the drug due to rapid [absorption](https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/absorption-pharmacokinetics) of the medium into the tablet core followed by prompt tablet disintegration under the effect of superdisintegrants. Orally disintegrating tablets provide an advantage particularly for pediatric and geriatric populations who have difficulty in swallowing conventional tablets and capsules. Additionally, pediatric patients may suffer from ingestion problems as a result of underdeveloped muscular and nervous Control. Moreover, patients traveling with little or no access to water, limit utility of orally administered conventional tablets or capsules. Rapid disintegration of tablet results in quick dissolution and rapid absorption which provide rapid onset of action. Moreover, drug candidates that undergo pre-gastric absorption when formulated as ODTs may show increased oral bioavailability. It provides good stability, accurate dosing, easy manufacturing, small packaging size, and easy to handle by patients. It is easy to administer for pediatric, geriatric, and institutionalized patients (especially for mentally retarded and psychiatric patients). Many technologies have come up for fast dissolve tablets like Zydis, OraSolv, DuraSolv, FlashTab and WowTab.Technologies like Zydis, FlashTab have resulted in tablets with a very low disintegration time, but poor mechanical strength. On the other hand, techniques like OraSolv, DuraSolv have resulted in products with sufficient mechanical strength but a comparatively longer disintegration time. Formulation of drugs as orally disintegrating tablets (ODTs) is one of the approaches to achieve enhanced patient acceptance toward orally solid dosage forms.

Furosemide (FUR), 5-(aminosulphonyl)-4-chloro-2-[(2-fuanyl-methyl) amino] benzoic acid, is a potent loop (high ceiling) diuretic used mainly in the management of hypertension. According to the biopharmaceutical classiﬁcation system (BCS), FUR is classiﬁed as a class IV drug due to its low solubility(5–20 mg/ml) and low permeability. Therefore, low oral bioavailability of FUR has been reported.

The aim of this study is to optimize, formulate & evaluate ODTs containing Furosemide. The effects of the superdisintegrants i.e. Crosspovidone, Croscarmellose sodium and Fenugreek powder etc. on the tablets disintegration and dissolution will be investigated.

1. **MATERIALS AND METHOD (10 Bold)**

## Furosemide was received as a gift sample from the Rajesh Chemicals Co. Mumbai. India. Microcrystalline cellulose, Mannitol, Cross carmellose sodium, Crospovidone, Aspartame and Magnesium stearate was received as a gift sample from Ozone International Mumbai, India., All other materials and chemicals used were of either pharmaceutical or analytical grade.

**Preparation of ODT Tablets:-**

Oral disintegrating tablet of Furosemide were prepared by using direct compression method according to the formulae as shown in the table 1. This method involves a simple procedure of blending of API with other ingredients and the resulted mixture is subjected to direct compaction. The required ingredients were taken in a mortar and the powder blend was mixed for a time period of 15-20 min by using mortar and pestle. Then each mixture was passed through sieve no.60 and finally magnesium stearate was added as lubricant and thoroughly mixed. It was then compressed by using 10 station tablet compression machine (Rimek minipress-II MT, Karnavati Ltd.) to get at 8 mm size of tablets each weighing 200 mg.

## Table No.-1: Formulation of Furosemide ODT Tablets:

## 

**Evaluation (Pre-compression) of flow properties of powder blends of factorial batches**

The characterization of flow properties of powder blends is important in tablet compression. The powder blends with good flow properties gives uniform die fill and consequently it gives the uniform tablet weight.

* **Bulk density**

The bulk density of powder is important parameter in the compressibility of the powder. The bulk density was between 0.34±0.02 to 0.37±0.02 gm/cm3

* **Tapped density**

The tapped density of powder is important parameters in the compressibility of the powder. The tapped density was found to 0.41±0.01 to 0.45 ± 0.02 gm/cm3

* **Carr’s index**

## The Carr’s index is indicator of compressibility. The value below 21% shows fair to passable compressibility. It was found to be 11.30±0.02 to 21.53±1.31 indicating passable compressibility.

* **Hausner’s ratio**

The Hausner’s ratio is another parameter indicating the flow properties. The value of ratio below 1.25 indicates good flow while above 1.25 indicates the poor flow. It was found to be 1.1±0.02 to 1.58±0.02 indicating good to passable flow ability.

* **Angle of repose**

The angle of repose can be correlated with type of flow of powder. The angle of repose 31 to 35 indicates the good flow while the angle of repose more 30 indicates poor flow properties and angle of repose below 30 indicates excellent flow properties. The angle of repose was found to be within the range of 27.00±1.12 to 28.00±0.90 indicating good flowability.

**Table No. 2: Evaluation (Pre-compression) parameters of all formulation (F1-F12)**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **formulation** | **Bulk density** | **Tapped density** | **Angle of repose** | **Compressibility index** | **Hausner’s ratio** |
| F1 | 0.34±0.02 | 0.42±0.015 | 28.52±2.37 | 13.52±0.11 | 1.58±0.13 |
| F2 | 0.35±0.02 | 0.41±0.01 | 28.60±1.94 | 12.54±0.12 | 1.30±0.05 |
| F3 | 0.38±0.01 | 0.43±0.01 | 28.43±0.90 | 17.23±1.09 | 1.24±0.04 |
| F4 | 0.35±0.01 | 0.44±0.01 | 28.00±1.97 | 21.53±0.86 | 1.17±0.05 |
| F5 | 0.36±0.01 | 0.41±0.02 | 27.54±1.55 | 14.55±3.16 | 1.17±0.03 |
| F6 | 0.34±0.01 | 0.44±0.015 | 27.00±1.94 | 11.30±0.74 | 1.18±0.06 |
| F7 | 0.34±0.02 | 0.45±0.02 | 28.63±1.12 | 18.36±1.99 | 1.14±0.02 |
| F8 | 0.37±0.02 | 0.41±0.30 | 28.00±2.05 | 17.35±0.85 | 1.18±0.04 |
| F9 | 0.35±0.02 | 0.43±0.02 | 27.20±1.39 | 15.28±0.36 | 1.16±0.03 |
| F10 | 0.35±0.02 | 0.41±0.02 | 28.15±1.39 | 17.56±0.84 | 1.21±0.02 |
| F11 | 0.35±0.01 | 0.41±0.02 | 27.63±0.90 | 18.96±0.84 | 1.17±0.02 |
| F12 | 0.36±0.01 | 0.44±0.01 | 28.65±1.09 | 19.85±0.86 | 1.18±0.03 |

**POST COMPRESSION STUDIES**

**1. Weight Variation**

20 tablets were selected and weighed collectively and individually. From the collective weight, average weight was calculated. Each tablet weight was then compared with average weight to assure whether it was within permissible limits or not. Not more than two of the individual weights deviated from the average weight by more than 7.5% for 200 mg tablets and none by more than double that percentage.

**2. Hardness test**

The hardness of tablet of each formulation was measured by Monsanto hardness tester. The hardness was measured in terms of kg/cm2. The hardness of tablet was found in between 3.3±0.30 to 4.3±0.30.

**3. Thickness**

The Thickness of tablet was measured by Vernier caliper & the Furosemide tablet of thickness were found in between the 2.30±0.45 to 2.70±0.05.

**4. Friability test**

This test is performed to evaluate the ability of tablets to withstand abrasion in packing, handling and transporting. Initial weight of 20 tablets is taken and these are placed in the Roche friabilator, rotating at 100 rpm for 4 min. The tablets are then taken out, dedusted and were weighed. The difference in the weight is noted and expressed as percentage.

**5. Content uniformity**

Twenty tablets were crushed and powder equivalent to weight of one tablet was dissolved in phosphate buffer 6.8. Then suitable dilutions were made and absorbance at 276 nm wavelength was taken by using a UV visible spectrophotometer. The content uniformity of Furosemide were found to be 95.23±1.09 to 99.36±0.48.

**6. Disintegration time**

Fast Disintegrating tablets apply the tests observe the tablets within the time limit all of the tablets have disintegrated. If 1 or 2 tablets fail to disintegrate completely repeat the test on 12 additional tablets, not less than 16 of the total of 18 tablets tested disintegrate completely. The Furosemide tablets were found in between the 14 sec. to 46 sec.

**In-vitro drug release studies:**

In-vitro drug release studies were carried out by using USP-type II dissolution apparatus.

900 ml of Phosphate buffer (pH 6.8) was placed in the dissolution flask maintained at a temperature of 37±0.50 C. One tablet was placed in the flask of the dissolution apparatus and was operated to run up to 30 mins at 50 rpm. At definite time intervals, 5 ml of dissolution medium was withdrawn, filtered and again replaced with 5 ml of fresh medium. Suitable dilutions were done with dissolution medium and were analyzed spectrophotometrically at λ max is 276 nm using a UV-spectrophotometer (Lab India; Mumbai). The in-vitro drug release of ODT tablets of Furosemide was shown in fig 5-8.

## Table No.-3: Evaluation (Post-compression) parameters of all formulation:

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Formulation** | **Hardness kg/cm2** | **Friability**  **(%)** | **Weight variation** | **Content uniformity** | **Disintegration time**  **(sec.)** | **Thickness** |
| F1 | 3.5±0.35 | 0.85±0.13 | 200.3±0.5 | 95.23±1.09 | 43 | 2.86±0.15 |
| F2 | 3.3±0.20 | 0.70±0.06 | 200.33±1.04 | 96.32±1.06 | 40 | 2.63±0.15 |
| F3 | 3.2±0.40 | 0.75±0.01 | 200.22±0.76 | 99.18±0.63 | 37 | 2.80±0.10 |
| F4 | 3.5±0.26 | 0.85±0.02 | 200±1.32 | 99.07±0.61 | 46 | 2.83±0.15 |
| F5 | 3.3±0.2 | 0.77±0.02 | 200.5±0.5 | 99.01±0.72 | 38 | 2.60±0.2 |
| F6 | 3.6±0.15 | 0.85±0.03 | 200.55±0.76 | 98.89±0.47 | 35 | 2.53±0.20 |
| F7 | 4.2±0.25 | 0.73±0.02 | 201.5±1.04 | 99.17±0.24 | 16 | 2.47±0.24 |
| F8 | 4.3±0.30 | 0.73±0.01 | 200.5±0.76 | 98.14±0.42 | 15 | 2.53±0.15 |
| F9 | 4.5±0.35 | 0.55±0.05 | 200.80±0.5 | 97.78±0.42 | 16 | 2.50±0.45 |
| F10 | 4.0±0.15 | 0.50±0.05 | 200.33±1.04 | 98.1±0.22 | 16 | 2.70±0.15 |
| F11 | 4.1±0.25 | 0.53±0.01 | 200.5±0.5 | 97.47±0.63 | 15 | 2.83±0.15 |
| F12 | 4.2±0.2 | 0.60±0.05 | 200.33±1.04 | 98.06±0.53 | 14 | 2.65±0.05 |

All values are represented as mean ±standard deviation (n=3)

Thickness, hardness, weight variation, & drug content are mean of n determination values are given in mean ± standard deviation.

**FTIR RESULT**

FTIR studies were conducted and the spectrum was recorded in the range of 4000-400cm-1.No significant interaction between drug and Excipients was observed. All the spectrum i.e. drug and Excipients were concordant with that of standard IR spectra of pure drug Furosemide.

**Figure No 1: FTIR spectra of Furosemide**

**Figure No 2: FTIR spectra of Furosemide + Crospovidone**




**Figure No 3: FTIR spectra of Furosemide + Fenugreek powder**



**Figure No 4: FTIR spectra of Furosemide +MCC+ Mannitol + Talc + Crospovidone + Croscarmellose sodium+ Fenugreek powder+ Aspartame+ Magnesium stearate.**

**Table No.4- List of Functional Group**

****

**Table No.5:- Dissolution Profiles of Formulations F1-F3.**

|  |  |  |  |
| --- | --- | --- | --- |
| Time | F1 | F2 | F3 |
| 0 | 0.00 | 0.00 | 0.00 |
| 5 | 32.68 | 36.27 | 38.87 |
| 10 | 44.84 | 46.85 | 49.46 |
| 15 | 52.27 | 54.90 | 57.52 |
| 20 | 68.13 | 65.58 | 68.22 |
| 25 | 71.10 | 76.32 | 78.97 |
| 30 | 79.27 | 81.93 | 82.00 |

**Figure No. -5: % drug release for F1-F3**

**Table No.6:- Dissolution Profiles of Formulations F4-F6**

|  |  |  |  |
| --- | --- | --- | --- |
| Time | F4 | F5 | F6 |
| 0 | 0.00 | 0.00 | 0.00 |
| 5 | 38.87 | 46.65 | 51.81 |
| 10 | 46.87 | 52.10 | 57.32 |
| 15 | 57.51 | 62.77 | 70.61 |
| 20 | 70.80 | 78.68 | 81.38 |
| 25 | 76.38 | 84.31 | 89.61 |
| 30 | 81.39 | 89.96 | 92.70 |

**Figure No. 6:- % drug release for F4-F6**

**Table No.7: Dissolution Profiles of Formulations F7-F9**

|  |  |  |  |
| --- | --- | --- | --- |
| Time | F7 | F8 | F9 |
| 0 | 0 | 0 | 0 |
| 5 | 33.68 | 36.27 | 41.46 |
| 10 | 46.84 | 41.66 | 46.88 |
| 14 | 54.88 | 52.27 | 57.52 |
| 20 | 68.16 | 57.75 | 63.03 |
| 25 | 73.72 | 68.45 | 73.75 |
| 30 | 79.32 | 81.80 | 89.73 |

**Figure No. 7:- % drug release for F7-F9**

**Table No. 8: Dissolution Profiles of Formulations F10-F12**

|  |  |  |  |
| --- | --- | --- | --- |
| **Time** | **F10** | **F11** | **F12** |
| 0 | 0.00 | 0.00 | 0.00 |
| 5 | 51.84 | 41.46 | 44.06 |
| 10 | 57.32 | 46.88 | 52.09 |
| 15 | 68.02 | 57.52 | 62.75 |
| 20 | 76.18 | 63.03 | 73.48 |
| 25 | 84.38 | 84.13 | 89.45 |
| 30 | 90.03 | 92.38 | 97.73 |

**Figure No. 8:- % drug release for F10-12**

**Table No.9: Kinetic release fit model of all Formulation**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Formulation no. | Zero order | First order | Matrix | Peppas | Hix crow | Fit |
| 1 | 0.9056 | 0.9881 | 0.9965 | 0.9905 | 0.9738 | Matrix |
| 2 | 0.8999 | 0.9902 | 0.9977 | 0.9923 | 0.9770 | Matrix |
| 3 | 0.8739 | 0.9864 | 0.9964 | 0.9923 | 0.9666 | Matrix |
| 4 | 0.8784 | 0.9986 | 0.9962 | 0.9875 | 0.9682 | Matrix |
| 5 | 0.8523 | 0.9883 | 0.9908 | 0.9704 | 0.9710 | Matrix |
| 6 | 0.8057 | 0.9895 | 0.9859 | 0.9771 | 0.9852 | First |
| 7 | 0.8967 | 0.9905 | 0.9986 | 0.9970 | 0.9724 | Matrix |
| 8 | 0.9052 | 0.9686 | 0.9895 | 0.9665 | 0.9666 | Matrix |
| 9 | 0.8872 | 0.9449 | 0.9866 | 0.9579 | 0.9585 | Matrix |
| 10 | 0.7777 | 0.9769 | 0.9807 | 0.9789 | 0.9448 | Matrix |
| 11 | 0.9137 | 0.9480 | 0.9840 | 0.9492 | 0.9692 | Matrix |
| 12 | 0.9087 | 0.9217 | 0.9932 | 0.9748 | 0.9745 | Matrix |

1. **CONCLUSION (10 Bold)**

Furosemide ODTs were successfully prepared using direct compression method. A full factorial design was a useful tool to optimize and evaluate the influence of type and concentration of diluents and concentration of superdisintegrant on optimizing Furosemide ODTs. There were good correlations between the predicted values and experimental data of the optimized formula validated by response surface optimization. The type and concentration of diluents and superdisintegrant concentration had a great influence on Furosemide ODTs properties. The disintegration time was significantly (P < 0.05) decreased by using Crospovidone & fenugreek seed powder instead of Croscarmellose sodium & sodium starch glycolate. Finally, Furosemide the composition of ODTs could be optimized so as to obtain rapid disintegration and drug dissolution along with acceptable tablets hardness and friability. This could enhance drug absorption and bioavailability, resulting in improved patient compliance and convenience.

**REFERENCES: (10 Bold)**

1. Parakh, S. And A. Gothoskar, A Review Of Mouth Dissolving Tablet Technologies. Pharmaceutical Technology, 2003. 27(11): P. 92-100.
2. Lieberman Ha, L.L. Schwartz Jb, Compressed Tablets By Direct Compression, And Compression Coated And Layer Tablets, In Pharmaceutical Dosage Forms. 1989, Marcel Dekker New York P. 195-284.
3. Rani Thakur, R. And A. Verma, Mouth Dissolving Tablets- Preparation Characterization And Evaluation: An Overview. Journal Of Pharmacy Research, 2012. 5(2): P. 993-1000.
4. Sreenivas, S., Et Al., Orodispersible Tablets: New-Fangled Drug Delivery System-A Review. Indian Journal Of Pharmaceutical Education, 2005. 39(4): P. 177.
5. Ghosh, T. A. Ghosh, And D. Prasad, A Review On New Generation Orodispersible Tablets And Its Future Prospective. International Journal Of Pharmacy And Pharmaceutical Sciences, 2011. 3(1): P. 1.
6. Chue, P. R. Welch, And C. Binder, Acceptability And Disintegration Rates Of Orally Disintegrating Risperidone Tablets In Patients With Schizophrenia Or Schizoaffective Disorder. Canadian Journal Of Psychiatry, 2004. 49(10): P. 701-703.
7. Seager, H. Drug Delivery Products And The Zydis Fast Dissolving Dosage Form\*. Journal Of Pharmacy And Pharmacology, 1998. 50(4): P. 375-382.
8. Dixit, S. Et Al. Fast Dissolving Tablet-A Promising Approach For Drug Delivery: A Review. Journal Of Pharmacy Research, 2012. 5(3): P. 1508-1513.
9. L Lachman, HA Liberman, Joseph L Kani G, The theory and practice of industrial pharmacy, Varghese publishing house, Bombay, **1990,** 3rd Edition, 315-317.
10. Kuchekar, B. A.C. Badhan, And H. Mahajan, Mouth Dissolving Tablets: A Novel Drug Delivery System. Pharma Times, 2003. 35(7).
11. Harmon, T. Emerging Technology Beyond The First Generation Of Orally Disintegrating Tablets September 1, 2006.
12. Chang, R.-K., Et Al., Fast-Dissolving Tablets. Pharmaceutical Technology, 2000. 24(6): P. 52-58.
13. Siddiqui, M.N. G. Garg, And P.K. Sharma, Fast Dissolving Tablets: Preparation, Characterization And Evaluation: An Overview. International Journal Of Pharmaceutical Sciences Review And Research, 2010. 4(2): P. 87-96.
14. Fu, Y. Et Al. Orally Fast Disintegrating Tablets: Developments, Technologies, Tastemasking And Clinical Studies. Critical Reviews™ In Therapeutic Drug Carrier Systems, 2004. 21(6).
15. T Shu, H Suzuki, K Hironaka, K Ito, *Chem Pharm Bull*., **2002,** 50(2), 193-198.
16. J Madan, AK Sharma, R Singh, *Trop J Pharm Res*., **2009,** 8(1), 63-70.